New Search

If you are not happy with the results below please do another search

Search
Generic filters

50 search results for:

31

Opill’s OTC launch will pave way for more oral contraceptives to become available in United States

An unmet need in the contraceptive field is availability and access for patients. Almost half of the 6.1 million pregnancies in the United States annually are unintended, so the approval of Opill to be sold over the counter without a prescription allows increased accessibility, promoting timely use and reducing barriers to family planning, according to GlobalData.

34

Top patient safety concerns of 2024

Challenges transitioning new clinicians from academic training to professional practice tops ECRI’s 2024 list of top 10 patient safety concerns for 2024 released by one of the nation’s largest patient safety organizations. ECRI researchers compiled the report by drawing on evidence-based research, data, and expert insights.

39

Opdivo to face direct competition with Keytruda and Padcev combination in bladder cancer space

Bristol Myers Squibb’s Opdivo was recently granted FDA approval in combination with cisplatin and gemcitabine as a first-line treatment for metastatic urothelial carcinoma. With this approval, Opdivo positions itself to compete with Merck & Co’s immune checkpoint inhibitor Keytruda in combination with Astellas and Pfizer’s Padcev, a nectin-4-directed antibody-drug conjugate, according to GlobalData.